CA2722365C - Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging - Google Patents
Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging Download PDFInfo
- Publication number
- CA2722365C CA2722365C CA2722365A CA2722365A CA2722365C CA 2722365 C CA2722365 C CA 2722365C CA 2722365 A CA2722365 A CA 2722365A CA 2722365 A CA2722365 A CA 2722365A CA 2722365 C CA2722365 C CA 2722365C
- Authority
- CA
- Canada
- Prior art keywords
- chemotherapy
- cells
- mice
- animal
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3045883A CA3045883C (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4768008P | 2008-04-24 | 2008-04-24 | |
| US61/047,680 | 2008-04-24 | ||
| PCT/US2009/041736 WO2009132320A2 (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045883A Division CA3045883C (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2722365A1 CA2722365A1 (en) | 2009-10-29 |
| CA2722365C true CA2722365C (en) | 2019-08-06 |
Family
ID=41217444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2722365A Active CA2722365C (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| CA3045883A Active CA3045883C (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045883A Active CA3045883C (en) | 2008-04-24 | 2009-04-24 | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2285218B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2011523626A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2722365C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2800327T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009132320A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012111790A1 (ja) * | 2011-02-17 | 2012-08-23 | 味の素株式会社 | 化学療法剤の抗腫瘍活性増強剤 |
| JP5752980B2 (ja) * | 2011-04-04 | 2015-07-22 | 日本メジフィジックス株式会社 | 腎臓トランスポーターの輸送能を抑制するための組成物 |
| CA2900782C (en) * | 2013-02-12 | 2022-09-27 | University Of Southern California | Methods and diets to protect against chemotoxicity and age related illnesses |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
| EP3115047B1 (en) * | 2014-03-07 | 2020-05-06 | Ajinomoto Co., Inc. | Debility preventative |
| EP3291693A4 (en) * | 2015-05-06 | 2019-04-03 | University of Southern California | FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER |
| CN112752575A (zh) * | 2018-09-27 | 2021-05-04 | 雀巢产品有限公司 | 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途 |
| WO2021123245A1 (en) | 2019-12-19 | 2021-06-24 | Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) | Nad-precursors and dietary restriction for treating age-related medical conditions |
| AU2020468941A1 (en) * | 2020-09-23 | 2023-03-23 | Aminovita S.L. | Metabolic cancer therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| US4574085A (en) * | 1981-05-15 | 1986-03-04 | Baxter Travenol Laboratories, Inc. | Method for using dialysis solution containing glycerol |
| FR2591893B1 (fr) | 1985-12-19 | 1988-11-10 | Centre Nat Rech Scient | Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes |
| US4981687A (en) * | 1988-07-29 | 1991-01-01 | University Of Florida | Compositions and methods for achieving improved physiological response to exercise |
| JPH0368514A (ja) * | 1989-08-09 | 1991-03-25 | Morishita Pharmaceut Co Ltd | 癌用アミノ酸製剤 |
| FR2673812B1 (fr) * | 1991-03-13 | 1994-04-01 | Roussel Uclaf | Nouvelles compositions destinees a etre utilisees en dietetique et en therapeutique et renfermant une combinaison particuliere de glucides et leurs applications. |
| JPH04352720A (ja) * | 1991-05-30 | 1992-12-07 | Tanabe Seiyaku Co Ltd | 癌患者用アミノ酸製剤 |
| WO1993006834A1 (en) * | 1991-10-07 | 1993-04-15 | Otsuka Pharmaceutical Factory, Inc. | Enteral preparation for cancer therapy |
| JP3380287B2 (ja) * | 1992-04-07 | 2003-02-24 | 麒麟麦酒株式会社 | 血中アルコール濃度上昇阻害飲料 |
| US6338856B1 (en) * | 1998-02-27 | 2002-01-15 | Texas Tech University | Seaweed supplement diet for enhancing immune response in mammals and poultry |
| JPH11332514A (ja) * | 1998-05-22 | 1999-12-07 | Nof Corp | バランス栄養食品 |
| US7115297B2 (en) * | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
| US7744930B2 (en) * | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| GB0416493D0 (en) * | 2004-07-23 | 2004-08-25 | Pitsiladis Yannis P | Hydrating composition |
| EP1731145A1 (en) * | 2005-05-25 | 2006-12-13 | Institut National De La Recherche Agronomique | Use of glycerol for improving cardiac function |
| EP2135604A4 (en) | 2007-03-26 | 2011-08-03 | Hirofumi Matsui | PREPARATION OF INFUSION FOR PATIENT SUFFERING FROM CANCER |
-
2009
- 2009-04-24 JP JP2011506488A patent/JP2011523626A/ja active Pending
- 2009-04-24 EP EP09734637.3A patent/EP2285218B1/en active Active
- 2009-04-24 CA CA2722365A patent/CA2722365C/en active Active
- 2009-04-24 ES ES09734637T patent/ES2800327T3/es active Active
- 2009-04-24 WO PCT/US2009/041736 patent/WO2009132320A2/en not_active Ceased
- 2009-04-24 CA CA3045883A patent/CA3045883C/en active Active
-
2015
- 2015-05-25 JP JP2015105690A patent/JP2015186480A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009132320A2 (en) | 2009-10-29 |
| JP2011523626A (ja) | 2011-08-18 |
| EP2285218B1 (en) | 2020-06-17 |
| JP2015186480A (ja) | 2015-10-29 |
| ES2800327T3 (es) | 2020-12-29 |
| CA3045883A1 (en) | 2009-10-29 |
| EP2285218A4 (en) | 2011-10-05 |
| EP2285218A2 (en) | 2011-02-23 |
| CA2722365A1 (en) | 2009-10-29 |
| WO2009132320A3 (en) | 2010-01-07 |
| CA3045883C (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8865646B2 (en) | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging | |
| CA3045883C (en) | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging | |
| Zhang et al. | Akt activation: A potential strategy to ameliorate insulin resistance | |
| Altea‐Manzano et al. | Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take | |
| US20230036788A1 (en) | Compositions and methods of using tyrosine kinase inhibitors | |
| Brandhorst et al. | Fasting and caloric restriction in cancer prevention and treatment | |
| Apostolova et al. | Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets | |
| Lee et al. | Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index | |
| Casirola et al. | α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice | |
| Nicastro et al. | An overview of the therapeutic effects of leucine supplementation on skeletal muscle under atrophic conditions | |
| ES2822178T3 (es) | Formulaciones dietéticas que promueven la regeneración de tejidos/órganos | |
| Zhou et al. | Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway | |
| US20080038321A1 (en) | Prophylactic/therapeutic compositions for liver diseases | |
| US12472159B2 (en) | Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects | |
| Zhao et al. | Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer | |
| BR112020009552A2 (pt) | combinação farmacêutica de inibidor da via de sinalização do receptor de andrógeno e de inibidor de p38 para uso no tratamento de câncer de próstata e uso de um inibidor de p38 para restaurar a sensibilidade à adt | |
| Ju et al. | Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC | |
| Hamers et al. | Trametinib alters contractility of paediatric Noonan syndrome-associated hypertrophic myocardial tissue slices | |
| Wojcik et al. | Melatonin as a pleiotropic molecule with therapeutic potential for type 2 diabetes and cancer | |
| Teixeira et al. | Mitochondria-targeted ROS scavenger JP4-039 improves cardiac function in a post-myocardial infarction animal model and induces angiogenesis in vitro | |
| Moreira et al. | Mitochondria as potential targets in antidiabetic therapy | |
| Zhang et al. | High-iron diet damages brown adipose tissue mitochondria and exacerbates metabolic hazards of a high-fat diet | |
| KR20120058047A (ko) | 스핑고신-1-포스페이트(sphingosine-1-phosphate) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물 | |
| AU2005226731A1 (en) | Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase | |
| Lee | Fasting-based differential stress resistance to enhance cancer treatment: A novel strategy to protect normal cells and sensitize cancer cells to chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140423 |